drugset / Trial / NCT04801043
To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.
RandomizedParallel-groupDouble-blindBasic science
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-min (± 3 min) IV infusion in healthy adult young females and in healthy adult elderly males and females.
Timeline
- Start
- 2021-03-02
- Primary completion
- 2021-10-30
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cilastatin | Small molecule | 500 mg | Intravenous |
| Subject | IMIPENEM ANHYDROUS | Small molecule | 500 mg | Intravenous |
| Subject | XNW4107 | Unknown | 250 mg | Intravenous |